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Abstract
Background: Prohormone convertase 1 is involved in maturation of peptides. Rare mutations in gene PCSK1, encoding 
this enzyme, cause childhood obesity and abnormal glucose homeostasis with elevated proinsulin concentrations. 
Common single nucleotide polymorphisms (SNPs) within this gene, rs6232 and rs6235, are associated with obesity. We 
studied whether these SNPs influence the prediabetic traits insulin resistance, β-cell dysfunction, or glucose 
intolerance.
Methods: We genotyped 1498 German subjects for SNPs rs6232 and rs6235 within PCSK1. The subjects were 
metabolically characterized by oral glucose tolerance test with glucose, insulin, proinsulin, and C-peptide 
measurements. A subgroup of 512 subjects underwent a hyperinsulinemic-euglycemic clamp.
Results: The minor allele frequencies were 25.8% for SNP rs6235 and 6.0% for rs6232. After adjustment for sex and age, 
we found no association of SNPs rs6235 and rs6232 with BMI or other weight-related traits (all p ≥ 0.07). Both minor 
alleles, adjusted for sex, age, BMI and insulin sensitivity were associated with elevated AUCproinsulin and AUCproinsulin/
AUCinsulin (rs6235: padditive model ≤ 0.009, effect sizes 8/8%, rs6232: pdominant model ≤ 0.01, effect sizes 10/21%). Insulin 
secretion was not affected by the variants (different secretion parameters, all p ≥ 0.08). The minor allele of SNP rs6232 
was additionally associated with 15% higher OGTT-derived and 19% higher clamp-derived insulin sensitivity (pdom ≤ 
0.0047), 4.5% lower HOMAIR (pdom = 0.02) and 3.5% lower 120-min glucose (pdom = 0.0003) independently of BMI and 
proinsulin conversion. SNP rs6235 was not associated with parameters of glucose metabolism.
Conclusions: Like rare mutations in PCSK1, the more common variants tested determine glucose-stimulated proinsulin 
conversion, but not insulin secretion. In addition, rs6232, encoding the amino acid exchange N221D, influences insulin 
sensitivity and glucose homeostasis.
Background
Proteolytic cleavage is an important step in the matura-
tion of several hormones that are derived from inactive
precursors [1,2]. One important enzyme that catalyzes
this processing is prohormone convertase 1. This pro-
tease [3] is selectively expressed in neuronal and endo-
crine tissues [4] and is active within dense core secretory
granules [2,3]. Among its numerous substrates [3,5] are
key hormones and neuropeptides for the regulation of
energy metabolism, including proopiomelanocortin, pro-
glucagon, and proinsulin [1,4,6-9].
Patients with prohormone convertase 1 deficiency
(MIM: #600955), a rare monogenic disease, suffer from
childhood obesity, small intestinal absorptive dysfunction
and various endocrine disturbances. They develop
hypoadrenalism, hypogonadotrophic hypogonadism and
abnormal glucose homeostasis with elevated proinsulin
levels due to insufficient prohormone processing [9-12].
Genome-wide linkage studies identified a genomic
locus on chromosome 5q to be associated with obesity
[13-16]. Among other genes, this locus harbors PCSK1,
and associations of two common single nucleotide poly-
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morphisms (SNPs) within this gene (rs6232 and rs6235,
minor allele frequency (MAF) = 5.4% and 27.3%, respec-
tively) with obesity were reported [6].
Since prohormone convertase 1 is involved in proinsu-
lin conversion and thereby in insulin maturation as well
as in body weight regulation, the present study examined
the association of the putatively obesity-related SNPs
rs6232 and rs6235 in PCSK1 with the prediabetic traits
insulin resistance, β-cell dysfunction, and glucose intoler-
ance.
Methods
Participants
We studied 1498 non-diabetic subjects from southwest-
ern Germany. The participants were selected from the
ongoing Tübingen Family Study which currently includes
~2000 individuals with an increased risk for type 2 diabe-
tes mellitus [17]. Selection was done based on the avail-
ability of all phenotype data used for the analyses.
Especially proinsulin levels for all time points during the
OGTT were not available for all subjects in the cohort.
Most (68.5%) of these subjects had a family history of dia-
betes, i.e., at least one second-degree relative with type 2
diabetes. Informed written consent was obtained from all
participants and the local Ethics Committee approved the
protocol. The OGTT revealed that 73.0% of the non-dia-
betic participants had normal glucose tolerance, 10.0%
had impaired fasting glycaemia, 9.6% had impaired glu-
cose tolerance and 7.3% had impaired fasting glycaemia
and impaired glucose tolerance.
Genotyping
DNA from whole blood was isolated using a commercial
DNA isolation kit (NucleoSpin, Macherey & Nagel,
Düren, Germany). Genotyping was performed using the
TaqMan assay (Applied Biosystems, Forster City, CA,
USA). The TaqMan genotyping reaction was amplified on
a GeneAmp PCR system 7000 and fluorescence was
detected on an ABI PRISM 7000 sequence detector
(Applied Biosystems). The genotyping success rates were
99.0% for rs6232 and 99.1% for rs6235. The genotypes
were verified in 50 randomly selected subjects by bidirec-
tional sequencing, and both methods resulted in 100%
identical results. Both SNPs were in Hardy-Weinberg
equilibrium (rs6232 p = 0.1 and rs6235 p = 0. 7). The
SNPs were incompletely linked (D' = 0.887, r2 = 0.145).
OGTT
After an overnight fast, subjects ingested a solution con-
taining 75 g glucose at 08:00 hours. Venous blood sam-
ples were obtained at 0, 30, 60, 90 and 120 min, and
plasma glucose, insulin, C-peptide and proinsulin con-
centrations were determined.
Hyperinsulinemic-euglycemic clamp
Clamp-derived insulin sensitivity was determined in a
subgroup of 512 subjects by a hyperinsulinemic-eugylce-
mic clamp with measurement of glucose and insulin. The
test was performed as described earlier [18].
Analytical procedures
Plasma insulin and proinsulin were determined by com-
mercial chemiluminescence assays for ADVIA Centaur
(Siemens Medical Solutions, Fernwald, Germany). Blood
glucose was measured using a bedside glucose analyzer
(glucose oxidase method; Yellow Springs Instruments,
Yellow Springs, OH, USA).
Calculations
The area under the curve (AUC) AUCIns30/AUCGlc30 was
calculated as (Ins0  + Ins30)/(Glc0  + Glc30). First-phase
insulin was determined from the OGTT as described ear-
lier [19] by calculating 1283 + 1.829 × Ins30 - 138.7 × Glc30
+ 3.772 × Ins0. AUC of glucose, insulin, C-peptide and
proinsulin during the OGTT were calculated according
to the trapezoid method as: 0.5 × (c0/2 + c30 + c60 + c90 +
c120/2) with c = concentration. HOMAIR was calculated as
(Glc0 × Ins0 × 2)/45. Insulin sensitivity during the OGTT
was estimated as proposed by Matsuda and DeFronzo
[20]: ISI = 10,000/√(Glc0·Ins0·Glcmean·Insmean).
Statistical analyses
Unless otherwise stated, data are given as arithmetic
means ± SEM. Data were logarithmically transformed
prior to statistical analysis. Hardy-Weinberg equilibrium
was tested using χ2 test. Differences in anthropometrics
and metabolic parameters between genotypes were
tested using multivariate linear regression analysis.
PCSK1  SNP rs6235 and SNP rs6232 were examined
under both an additive (add) and a dominant inheritance
model (dom). However, only the dominant inheritance
model was interpreted for SNP rs6232 because of this
SNP's low MAF of 6% (only 5 participants were homozy-
gous for the minor allele). All data were adjusted for gen-
der and age. The glucose concentrations and insulin
sensitivity indices were additionally adjusted for BMI,
and proinsulin concentrations and insulin secretion
parameters were additionally adjusted for OGTT-derived
insulin sensitivity index and BMI.
Differences with a p-value < 0.05 were considered to
indicate nominal associations. After correction for the
two unlinked SNPs tested and the endpoints anthropo-
metrics, insulin secretion, and insulin sensitivity (accord-
ing to Bonferroni), results with values of p < 0.0085 were
considered statistically significant. The JMP 7.0 (SAS
Institute, Cary, NC, USA) statistical software package was
used.Heni et al. BMC Medical Genetics 2010, 11:86
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Power calculation
Using two tailed t-test, the study was sufficiently powered
(1-beta ≥ 0.8) to detect an effect size of 15% for SNP
rs6235 and 22% for SNP rs6232 (dominant inheritance
model, p = 0.05). Power calculations were performed
using G*power 3.0 software available at http://www.psy-
cho.uni-duesseldorf.de/aap/projects/gpower/.
Results
The observed MAF for SNP rs6235 was 25.8% (reported
27.3% [6]) and for rs6232 6.0% (reported 5.4% [6]).
After appropriate adjustment, both minor alleles of the
PCSK1 SNPs rs6232 and rs6235 were neither associated
with BMI nor with weight-related traits, like waist cir-
cumference and total body fat (all p ≥ 0.07, tables 1 + 2).
The frequency of obesity (BMI < 30 versus BMI ≥ 30 kg/
m2) in our cohort was not influenced by the risk alleles
(all p ≥ 0.4).
None of the SNPs revealed association with fasting pro-
insulin concentrations (all p ≥ 0.1, tables 1 + 2). However,
upon glucose ingestion, subjects carrying the minor
alleles showed an association with higher proinsulin con-
centrations (rs6232 nominally associated, pdom = 0.0104;
rs6235 significantly associated with AUCProins, padd  =
0.0018; adjusted effect sizes 10/8%; tables 1 + 2) and nom-
inally lower proinsulin-to-insulin conversion (AUCProins/
AUCins) compared to those with the major allele (rs6232,
pdom = 0.0094; rs6235, padd = 0.0090; adjusted effect sizes
21/8%; tables 1 + 2, figure 1A+1D) and this finding was
consistent when adjusting for insulin sensitivity or not.
Both variants were not associated with differences in
insulin secretion (all indices used p ≥ 0.08, tables 1 + 2),
and SNP rs6235 was furthermore neither associated with
glucose nor with insulin levels during the OGTT (all p ≥
0.2, figure 1B and 1C).
In addition to these findings, the minor allele of SNP
rs6232, but not that of SNP rs6235, was significantly asso-
ciated with decreased 120-min blood glucose (pdom =
0.0003, table 1, figure 2) and nominally associated with
decreased fasting insulin levels (pdom = 0.0297, table 1).
Insulin sensitivity derived from the OGTT was signifi-
cantly increased (pdom = 0.0010, adjusted effect size 15%,
table 1, figure 2) and insulin resistance derived from fast-
ing state (HOMAIR) was accordingly nominally decreased
in carriers of the minor allele (pdom = 0.0232, table 1 and
figure 2). The effect on OGTT-derived insulin sensitivity
remained significant even after adjustment for gender,
age, BMI, AUCProins/AUCIns, and first-phase insulin
secretion (pdom = 0.0033).
To confirm that the association with insulin sensitivity
did not solely reflect altered insulin levels due to impaired
prohormone processing, we analyzed insulin sensitivity
measured by exogenous administration of insulin during
hyperinsulinemic-euglycemic clamp. Again, SNP rs6232,
but not SNP rs6235 was associated with significantly
increased insulin sensitivity (pdom  = 0.0047; adjusted
effect size 19%; table 1).
To analyze subjects with low risk of type 2 diabetes
mellitus versus those with a high risk, we stratified for
family history of diabetes. This stratification did not pro-
duce consistent results, probably due to the limited
power of the subgroups.
Discussion
Association of PCSK1 with weight-related traits
In our cohort, the reported association of the common
variants rs6232 and rs6235 within the PCSK1 gene with
BMI and obesity could not be replicated. This is most
likely explained by the limited power of our study to
detect relatively small effect sizes of the SNPs on BMI and
obesity. The effect sizes detectable in our study were as
small as 15%, and for the established obesity risk locus
FTO an effect size of about 10% could be demonstrated
[21].
Association of PCSK1 with proinsulin levels
In the present study, we found that the minor alleles of
both candidate SNPs in the PCSK1 gene are associated
with significantly higher glucose-stimulated proinsulin
levels indicating reduced proinsulin conversion, while
insulin secretion was unaffected. These findings were not
altered by adjustment for insulin sensitivity.
Basal proinsulin levels were unaffected by the variants
in  PCSK1. Thus, under basal conditions the enzyme
cleaves sufficient amounts of proinsulin. However, in the
state of much higher secretory demands following a glu-
cose load, proinsulin levels and proinsulin-to-insulin
ratios were increased in carriers of both SNPs and this
points to insufficient insulin maturation.
Both SNPs in the PCSK1  gene alter the amino acid
sequence of the protein. SNP rs6232 changes asparagine
to aspartic acid (N221D) in the catalytic domain and
leads to a 10% reduction of activity, while SNP rs6235
substitutes serine by threonine (S690T) without any
effect on the enzymatic activity [6]. Reduced enzymatic
activity due to SNP rs6232 can plausibly explain this
observation, though the mechanism is less clear in the
case of the other SNP, rs6235. The substituted amino acid
by that variation could possibly influence binding of regu-
lators of the enzyme's activity, its localization within the
β-cell, or the available number of prohormone convertase
1 molecules via altered stability. All these effects could
theoretically influence prohormone conversion.
Although both PCSK1  SNPs affect proinsulin levels,
they do not alter insulin secretion after glucose stimula-
tion. Thus, the enzyme does not represent the rate-limit-Heni et al. BMC Medical Genetics 2010, 11:86
http://www.biomedcentral.com/1471-2350/11/86
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Table 1: Associations of PCSK1 SNP rs6232 with anthropometrics, metabolic parameters, and proinsulin conversion
SNP rs6232 (encoding N221D)
Genotype AA AG GG βadj ± SEM pdom padd
N (f/m) 1305(875/430) 173(106/67) 5(3/2) - - -
Age (years) 39 ± 0.4 40 ± 1 37.6 ± 4 - - -
BMI (kg/m2) 28.5 ± 0.2 28.3 ± 0.6 29.1 ± 6.1 -0.003 ± 0.001 0.8 1.0
Waist circumference (cm) 93.4 ± 0.5 93.1 ± 1.2 82.3 ± 3.5 -0.005 ± 0.007 0.6 0.9
Total body fat (%) 31.0 ± 0.3 29.6 ± 0.8 30.4 ± 7 -0.017 ± 0.013 0.07 0.4
Fasting glucose (mmol/l) 5.1 ± 0.1 5.1 ± 0.1 5.4 ± 0.4 -0.004 ± 0.004 0.3 0.2
Glucose120-min (mmol/l) 6.3 ± 0.1 5.9 ± 0.1 6.8 ± 1.2 -0.035 ± 0.010 0.0003 0.0006
Fasting insulin (pmol/l) 63 ± 1 56 ± 3 59.8 ± 33 -0.041 ± 0.019 0.0297 0.07
Insulin sensitivity, OGTT (AU) 16.3 ± 0.3 18.5 ± 0.9 25.8 ± 7 0.068 ± 0.020 0.0010 0.0030
Insulin sensitivity, clamp-derived (AU)
(N = 512)
0.083 ± 0.003 
(N = 443)
0.098 ± 0.007 
(N = 68)
0.135 (N = 1) 0.085 ± 0.030 0.0047 -
HOMAIR (mU × mmol × l-2) 2.4 ± 0.1 2.1 ± 0.1 2.7 ± 1.8 -0.045 ± 0.020 0.0232 0.07
AUCIns30/AUCGlc30 (×10-9) 41.2 ± 0.9 36.8 ± 2.0 28.1 ± 8.3 -0.001 ± 0.017 1.0 0.6
First-phase insulin (pmol/l) 1267 ± 24 1160 ± 53 1046 ± 273 0.015 ± 0.017 0.4 0.7
AUCC-Pep/AUCGlc (×10-9) 319 ± 3 319 ± 8 272 ± 29 0.020 ± 0.011 0.08 0.2
Proinsulin0-min (pmol/l) 5.8 ± 0.2 5.6 ± 0.4 12.8 ± 8.4 0.053 ± 0.038 0.2 0.2
Proinsulin30-min (pmol/l) 11.8 ± 0.4 11.9 ± 0.7 18.6 ± 3.7 0.073 ± 0.035 0.0377 0.0190
AUCProins (pmol/l) 36.2 ± 1.0 37.2 ± 2.4 52.1 ± 12.7 0.074 ± 0.030 0.0141 0.0089
Fasting proinsulin/fasting insulin 0.128 ± 0.002 0.135 ± 0.003 0.179 ± 0.008 0.040 ± 0.039 0.3 0.3
Proinsulin30-min/insulin30-min 0.036 ± 0.004 0.035 ± 0.002 0.064 ± 0.004 0.079 ± 0.037 0.0346 0.0158
AUCProins/AUCIns 0.050 ± 0.016 0.058 ± 0.034 0.111 ± 0.017 0.079 ± 0.030 0.0094 0.0026
Data represent unadjusted means ± SEM. For statistical analysis, data were ln-transformed and adjusted for gender and age. Glucose 
concentrations and insulin sensitivity indices were additionally adjusted for BMI. Proinsulin values as well as insulin secretion parameters were 
additionally adjusted for BMI and insulin sensitivity (OGTT). AUC - area under the curve; βadj - effect sizes from the adjusted dominant model; BMI 
- body mass index; HOMAIR - homeostasis model assessment-estimated insulin resistance; OGTT - oral glucose tolerance test; padd - p-values from 
the additive inheritance model; pdom - p-values from the dominant inheritance model; SNP - single nucleotide polymorphism. p-values 
withstanding Bonferroni correction for multiple comparisons are given in bold.Heni et al. BMC Medical Genetics 2010, 11:86
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Table 2: Associations of PCSK1 SNP rs6235 with anthropometrics, metabolic parameters, and proinsulin conversion
SNP rs6235 (encoding S690T)
Genotype GG GC CC βadj ± SEM pdom padd
N (f/m) 817(537/280) 560(377/183) 108(72/36) - - -
Age (years) 39 ± 1 40 ± 1 38 ± 1 - - -
BMI (kg/m2) 28.2 ± 0.3 28.7 ± 0.3 29.3 ± 0.8 0.016 ± 0.010 0.2 0.3
Waist circumference (cm) 92.9 ± 0.6 93.9 ± 0.7 94.9 ± 2.0 0.009 ± 0.007 0.2 0.9
Total body fat (%) 30.7 ± 0.4 31.0 ± 0.5 31.7 ± 1.0 0.014 ± 0.014 0.7 0.5
Fasting glucose (mmol/l) 5.1 ± 0.1 5.1 ± 0.1 5.1 ± 0.1 -0.004 ± 0.004 0.2 0.3
Glucose120-min (mmol/l) 6.2 ± 0.1 6.3 ± 0.1 6.3 ± 0.2 0.005 ± 0.011 0.7 0.8
Fasting insulin (pmol/l) 61 ± 2 64 ± 2 63 ± 5 0.021 ± 0.027 0.8 0.6
Insulin sensitivity, OGTT (AU) 16.8 ± 0.4 16.4 ± 0.5 16.0 ± 0.9 -0.018 ± 0.029 0.7 0.7
Insulin sensitivity, clamp-
derived (AU)
(N = 512)
0.088 ± 0.003
(N = 286)
0.080 ± 0.004
(N = 191)
0.091 ± 0.009
(N = 35)
-0.023 ± 0.021 0.3 0.4
HOMAIR (mU × mmol × l-2) 2.4 ± 0.1 2.5 ± 0.1 2.5 ± 0.2 0.017 ± 0.029 0.9 0.6
AUCIns30/AUCGlc30 (×10-9) 40.4 ± 1.0 40.2 ± 1.3 46.0 ± 3.7 0.022 ± 0.026 0.9 0.6
First-phase insulin (pmol/l) 1247 ± 29 1251 ± 35 1383 ± 97 0.014 ± 0.024 1.0 1.0
AUCC-Pep/AUCGlc (×10-9) 318 ± 3.6 316 ± 4.4 343 ± 13 0.017 ± 0.014 1.0 0.2
Proinsulin0-min (pmol/l) 5.6 ± 0.2 5.9 ± 0.3 7.0 ± 0.9 0.081 ± 0.041 0.1 0.1
Proinsulin30-min (pmol/l) 11.2 ± 0.3 12.2 ± 0.7 16.5 ± 2.6 0.117 ± 0.038 0.0286 0.0059
AUCProins (pmol/l) 34.2 ± 1.0 37.0 ± 1.5 49.1 ± 6.7 0.105 ± 0.034 0.0404 0.0018
Fasting proinsulin/fasting 
insulin
0.126 ± 0.004 0.129 ± 0.003 0.147 ± 0.014 0.062 ± 0.044 0.2 0.1
Proinsulin30-min/insulin30-min 0.036 ± 0.005 0.035 ± 0.002 0.047 ± 0.011 0.105 ± 0.041 0.0208 0.0123
AUCProins/AUCIns 0.048 ± 0.001 0.053 ± 0.003 0.068 ± 0.011 0.085 ± 0.035 0.0324 0.0090
Data represent unadjusted means ± SEM. For statistical analysis, data were ln-transformed and adjusted for gender and age. Glucose 
concentrations and insulin sensitivity indices were additionally adjusted for BMI. Proinsulin values as well as insulin secretion parameters were 
additionally adjusted for BMI and insulin sensitivity (OGTT). AUC - area under the curve; βadj - effect sizes from the adjusted dominant model; BMI 
- body mass index; HOMAIR - homeostasis model assessment-estimated insulin resistance; OGTT - oral glucose tolerance test; padd - p-values from 
the additive inheritance model; pdom - p-values from the dominant inheritance model; SNP - single nucleotide polymorphism. p-values 
withstanding Bonferroni correction for multiple comparisons are given in bold.Heni et al. BMC Medical Genetics 2010, 11:86
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ing step in insulin secretion which is in contrast to SNPs
in diabetes risk genes which influence both proinsulin
conversion and insulin secretion [22].
Association of PCSK1 SNP rs6232 with insulin sensitivity
Furthermore, the putative obesity risk allele of SNP
rs6232 was unexpectedly associated with increased insu-
lin sensitivity (fasting, OGTT-derived, and hyperinsu-
linemic euglycemic-clamp derived) and reduced 120-min
glucose levels independently of BMI and proinsulin con-
version. The similar findings with different independent
measurements of insulin sensitivity as well as the inverse
influence on 120-min blood glucose argue against a mere
statistical type 1 error.
Since only SNP rs6232 in the PCSK1 gene, the one that
decreases the enzyme's catalytic activity [6], influences
insulin sensitivity, independently of BMI and proinsulin
conversion, and since there is a long list of potential sub-
strates of the prohormone convertases [3-5], it seems rea-
sonable to speculate that the enzyme also cleaves factors
that modulate insulin sensitivity (e.g. BNDF [23]).
In most cases, obesity is associated with insulin resis-
tance. However, a proportion of overweight/obese per-
sons display a phenotype of obesity with is metabolically
benign and characterized by high insulin sensitivity [17].
Since the minor allele of SNP rs6232 was associated with
higher insulin sensitivity in our study and with obesity in
a large metaanalysis including more then 13,000 subjects
[6], we hypothesize that this allele may promote a kind of
obesity, which is more benign.
Increased proinsulin levels are reported to be a marker
of insulin resistance [24]. Interestingly, for carriers of
Figure 1 Plasma proinsulin (A), glucose (B), and insulin (C) concentrations as well as proinsulin-to-insulin ratio (D) during OGTT in carriers 
of the PCSK1 SNP rs6235. Data are given as means +/- SEM. P-values for AUC adjusted for gender, age, BMI, and insulin sensitivity are given. Black 
boxes: homozygous carriers of the minor allele; white circles: heterozygous carriers; black circles: homozygous carriers of the major allele.
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PCSK1 SNP rs6232 it is the other way round: Those with
higher proinsulin concentrations during the OGTT have
also increased insulin sensitivity. Similar findings are
reported in another publication where insulin resistance
was associated with enhanced proinsulin processing in
subjects with normal glucose tolerance [25]. Hence,
increased proinsulin concentration can not generally be
seen as a marker of insulin resistance.
Limitations
Our study was underpowered to detect the previous
reported associations of the PCSK1 variants with obesity.
The associations with proinsulin conversion and insulin
sensitivity found in this study clearly need replication in
other cohorts, in particular, the unexpected association of
SNP rs6232 with insulin sensitivity. Furthermore, efforts
should also be undertaken to identify prohormone con-
vertase 1 substrates that alter insulin sensitivity and to
further characterize these mechanisms. Studies on the
molecular level could additionally help to answer the
question how PCSK1's SNP rs6235 influences proinsulin
levels without changing the enzyme's activity.
Conclusions
In conclusion, our data suggest that the common genetic
variants rs6232 and rs6235 within PCSK1 determine glu-
cose-stimulated proinsulin conversion, but not insulin
secretion. In addition, rs6232, encoding the mutation
N221D, influences glucose homeostasis and insulin sensi-
tivity independently of BMI and proinsulin concentra-
tions.
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Figure 2 Association of rs6232 (N221D) in PCSK1 gene with insulin sensitivity derived from OGTT, insulin resistance derived from the fast-
ing state (HOMAIR) and 120-min glucose. Data were adjusted for BMI, age and gender (dominant inheritance model).
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